Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink  by Macedo, Ana Filipa et al.
Thrombosis Research 136 (2015) 250–260
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresFull Length ArticleDeterminants of oral anticoagulation control in new warfarin patients:
analysis using data from Clinical Practice Research DatalinkAna Filipa Macedo a,⁎, James Bell b, Ciaran McCarron a, Rachel Conroy c, James Richardson c, Anna Scowcroft a,
Tom Sunderland a, Naj Rotheram c,⁎
a Market Access Pricing & Outcomes Research, Boehringer-Ingelheim, UK
b Biometrics & Data Management, Boehringer-Ingelheim, UK
c Medical Affairs – Cardiovascular, Boehringer-Ingelheim, UK⁎ Corresponding authors.
E-mail addresses: ﬁlipa_macedopt@hotmail.com (A.F.
naj.rotheram@boehringer-ingelheim.com (N. Rotheram).
http://dx.doi.org/10.1016/j.thromres.2015.06.007
0049-3848/© 2015 The Authors. Published by Elsevier Ltds u m m a r ya r t i c l e i n f oArticle history:
Received 19 March 2015
Received in revised form 18 May 2015
Accepted 4 June 2015
Available online 9 June 2015
Keywords:
warfarin
oral anticoagulants
international normalized ratio (INR)
time in therapeutic range (TTR)
predictors
real world data
Background: The safety and effectiveness of warfarin therapy depends critically on the quality of anticoagulation
control, often assessed using the percentage time in therapeutic International Normalised Ratio (INR) range
(TTR). We aimed to identify patient characteristics related to anticoagulation control with warfarin, measured
by TTR.
Method:Wecarried out a population-based study using the Clinical Practice Research Datalink, including two co-
horts of patients starting warfarin after a ﬁrst diagnosis of atrial ﬁbrillation (AF) or venous thromboembolism
(VTE) between 2000 and 2013. We used multivariate mixed regression and logistic regression models to predict
the fully-adjusted effect of each predictor variable upon TTR.
Results: The study population comprised 29,717 incident AF and 19,113 incident VTE patients who initiated war-
farin. In real world clinical practice a minority of patients achieve good anticoagulation control with warfarin
(44% AF and 36% VTE patients had TTR ≥ 70%). Poor anticoagulation control driven by subtherapeutic INRs was
observed in younger patients (b45 years) and in AF patients with increased number of hospitalisations. Poor
anticoagulation control driven by sub and/or supratherapeutic INRs was seen in AF and VTE patients current
smokers, in patients using medications for pain and in VTE patients with active cancer.
Conclusion: In a realworld clinical practice there is a high amount of unpredictable inter-individual TTR variability
and in some patients good anticoagulation control ismore challenging than in others. These ﬁndingsmay help to
identify patients whowill require closermonitoring or innovative strategies to optimise the outcomes of oral an-
ticoagulant therapy.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
The effectiveness of warfarin has been well established both in the
prevention of stroke and systemic embolism in patients with non-
valvular atrial ﬁbrillation (AF) and in the treatment and secondary pre-
vention of venous thromboembolism (VTE) [1,2]. However, the safety
and effectiveness of warfarin therapy depends critically on regular In-
ternational Normalised Ratio (INR) monitoring to maintain its effect
within a narrow therapeutic range (of 2.0 to 3.0), where warfarin treat-
ment has been shown to offer an acceptable beneﬁt:risk ratio [3–5].
Long-term INR control is often summarised using the percentage of
time spent in therapeutic range (TTR) [6–14]. Despite the importance of
good anticoagulation control for patients on warfarin, few studies haveMacedo),
. This is an open access article underinvestigated patient-level predictors of good TTR [15–18]. In a large co-
hort of patients from the Veterans Health Administration database in
the United States (VARIA registry), factors including female gender,
age less than 55 years, ethnicity, repeat hospitalisations, multiple drug
prescriptions, alcohol abuse, cancer, dementia, and chronic liver disease
were identiﬁed as predictors of poor anticoagulation control [17]. An-
other study including participants from the Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM) trial incorporated
similar patient-related factors in a score to predict poor INR control
(SAMe-TT2R2) [18].
Although these ﬁndings need external validation in different real
world settings, they emphasise the need for better strategies to identify
patients who are poor candidates for warfarin therapy, who require fur-
ther monitoring, or who are likely to beneﬁt from non-vitamin K oral
anticoagulants (NOACs). Data from an observational study conducted
in the United Kingdom (UK) suggests that warfarin therapy with an av-
erage TTR of less than 40% is not signiﬁcantly different in terms of mor-
tality beneﬁt than no warfarin at all [19].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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need to critically examine a patient’s suitability forwarfarin therapy, es-
pecially in the context of a patient’s likely ability to achieve acceptable
TTR [23,24].
In the present study we used computerised medical records derived
from primary care in the UK to identify patient demographic and clinical
factors related to anticoagulation controlwithwarfarin,measured as TTR.
2. Method
We carried out a population-based retrospective study using data
from the Clinical Practice Research Datalink (CPRD) linked to Hospital
Episode Statistics (HES).
2.1. Data Sources
The CPRD is a collection of anonymised longitudinal electronic
health records from primary care in the UK, hosted by theUKMedicines
and Healthcare products Regulatory Agency (MHRA). All the data from
patients is anonymised and no personal details are shared with re-
searchers. Data collection started in 1987. It includes diagnostic and pre-
scribing information, as well as information on lifestyle characteristics
formore than 13million patients frommore than 600 general practices.
The database is broadly representative of the UK population [25] and
several studies have conﬁrmed its validity for pharmacoepidemiological
research [26–30]. The National HES data contain details of all admis-
sions to National Health Service (NHS) hospitals in England and is
linked individually and anonymously to CPRD via the NHS number.
The protocol for this studywas approved by theMHRA Independent
Scientiﬁc Advisory Committee (Reference 14_068).
2.2. Study Population
We included in the study two cohorts of patients fromCPRD. Patients
with ﬁrst diagnosis of AF and patients with ﬁrst diagnosis of VTE, from 1
January 2000 up until 31 December 2013.Within this time period, study
start dates were deﬁned as whichever occurred later; the patient’s ﬁrst
registration date or the practice’s up-to-standard date (the date the
practice began contributing research quality data to CPRD). Study end
dates were derived using the earliest of the patient’s transfer-out date,
death date or the practice’s last collection date. The study start and
end dates ensure all patients are active with their practices and contrib-
uting good quality data to CPRD. Thedate of theﬁrst prescription ofwar-
farin (new users) on or after AF or VTE diagnosis was termed the index
date, the reference time point used for all analyses.
Inclusion criteria included adult patients who had been registered
for at least 12 months in CPRD before their ﬁrst diagnosis of AF or VTE,
to avoid including people who had been diagnosed prior to inclusion
in the CPRD. Patients were excluded if they had a record of warfarin
therapy within one year before their ﬁrst diagnosis of AF or VTE. We
also excluded AF patients with history of valve repair/replacement, pa-
tients with VTE during pregnancy (as warfarin use is contraindicated)
and patients who had a record of a non-vitamin-K oral anticoagulant
(i.e. dabigatran, rivaroxaban or apixaban) within one year of the index
date, because wewould not be able to reliably attribute anticoagulation
control to warfarin.
Incident AF or VTE diagnosis and warfarin prescriptions were
ascertained fromCPRDusing Read codes (Additionalﬁle: List S1), taking
the date of the ﬁrst record.
2.3. Dependent Variable: Time in Therapeutic Range (TTR)
The primary outcome under investigation was the Time in Thera-
peutic Range (TTR) in the ﬁrst 12 months of warfarin treatment, calcu-
lated according to F.R. Rosendaal’s algorithm [31]. This time period was
chosen because INR control in the ﬁrst 12 months of warfarin therapyhas been shown to be the best predictor of subsequent INR control
[32]. Thus patients were excluded from the study if they had less than
12 months of observation in CPRD after the index date.
For each patient, TTR was calculated from the date of the ﬁrst INR
measurement at the start of the warfarin exposure until the last INR
during the 12months of observation. For patientswho stoppedwarfarin
treatment before 12 months, the date of stopping treatment was
assumed as 45 days after the last recorded prescription (based on
30-day of prescription coverage, plus 15-day elimination period). If
the last INR measurement during the warfarin exposure period oc-
curred within the 45 days after the last recorded warfarin prescrip-
tion, it was included in the analysis.
We excluded extreme supratherapeutic INR values (INR N 20) from
the TTR analysis because these are likely to be related to recordmistakes
and may bias overall results. Patients with less than two INR tests re-
corded in theﬁrst 12months of treatment and/or only onewarfarin pre-
scription were also excluded from the TTR analysis. A comparison
between patients included in the TTR analysis and those excluded can
be found in the online supplement (Additional ﬁle: Table S1).
2.4. Predictor Variables
We investigated the effect of the following patient-related factors on
anticoagulation control:
Demographic variables: Sex, age, ethnicity, socioeconomic depriva-
tion (measured by Townsend Deprivation Score) and main spoken
language [17,18].
Clinical variables: Body mass index (BMI), smoking history, alcohol
consumption and substance abuse (non-alcohol) [17,18,32,33]. Co-
morbidities that are shown to worsen anticoagulation control, that
are treated with medications that interact with warfarin or that are
associated with chaotic lifestyle or poor adherence: acute respirato-
ry infection, cancer, chronic liver disease, chronic kidney disease,
chronic lung disease (COPD and asthma), hyperthyroidism, hypo-
thyroidism, epilepsy, bipolar disorder, dementia, major depression,
congestive heart failure, hyperlipidaemia, hypertension, diabetes,
vascular disease (prior myocardial infarction, peripheral artery dis-
ease or aortic plaque), history of stroke, history of bleeding, chronic
use of pain medication, osteoarthritis and rheumatoid arthritis
[15–18,34–39].
We further characterised each patient’s illness burden by the number
of prespeciﬁed comorbidities, aswell as by the number of hospitalisations
in the 12months before index date. Multiple comorbidities are known to
negatively affect TTR [18], and repeated hospitalisations have been iden-
tiﬁed as one of the most important predictors of a lower TTR [17].
Predictor variables were assessed at baseline (most recentmeasure-
ment before indexdate). Table S2 in the online supplement provides
further detail of the deﬁnitions and derivation of these variables in
CPRD.
2.5. Data Management and Statistical Analysis
All data management and statistical analysis were performed using
SAS software, with separate analyses conducted for patients with AF
and VTE diagnosis.
Missing data was treated as a separate category within each variable
(“unknown”) and included in all statistical models. Variables withmore
than 75% missing values and/or fewer than 10 patients were excluded
from all analyses.
In the primary analyses, we examined the fully-adjusted effect of
each predictor variable upon TTR using a multivariate mixed regression
model, including practice as a random effect. As a sensitivity analysis a
ﬁxed-effect mixed regression model was ﬁtted, excluding practice as a
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served values of TTR, since patients who consult their general practi-
tioner more often have more blood tests, thereby increasing the
likelihood of detection of abnormal INR levels, we further adjusted the
analysis for patient consultation rate (deﬁned as the number of times
a patient initiated contact with a general practice in the 12 months
prior to index date).
To combat inﬂation of the type I error rate due to multiple testing,
Bonferroni adjustment was employed for each analysis. Statistical sig-
niﬁcance was determined using signiﬁcance thresholds equivalent to a
family-wise adjusted (FWA) value ofα=0.05 – all conﬁdence intervals
reported are the 95% FWA CI, corresponding to a 99.918% CI. The corre-
sponding unadjusted p-values required for signiﬁcance are reported
with the results table for each analysis.
We assessed the possible effect modiﬁcation between each variable
and gender, age and deprivation. To assess the impact on TTR of the ini-
tiation phase of warfarin therapy and of the frequency of INR measure-
ments (e.g. due to planned interruptions) [40–42] we also conducted
two sensitivity analyses, one stratiﬁed according to ≤ 6 months
and N 6 months of warfarin treatment and the other restricted to the
group of patients with more than 8 INR tests.
As a secondary analysis method, we used logistic regression models
to test the ability of patient-related characteristics to predict the
quality of anticoagulation control. We deﬁned poor anticoagulation
control as TTR b 70% [19]. We further explored the patterns of poor
anticoagulation control by deﬁning two new metrics; time spent
under range (TUR; INR b 2) and time spent over range (TOR; INR N 3).
For these, we deﬁned cut-offs of TUR N 30% and TOR N 30%. These cut-
offs were established to ensure that to ﬁt either criterion, individuals
must also, by deﬁnition, have TTR b 70%. We then sought to identify
characteristics that were signiﬁcantly associated with at least 30% of
time spent with INR b2.0 (TUR) or at least 30% of time spent with
INR N 3.0 (TOR). All logistic regression analyses were performed upon
the patient set comprising thosewith 8 ormore INR tests (23,662 AF pa-
tients and 12,909 VTE patients). This was used to ensure more accurate
classiﬁcation of patients, with lower granularity of TTR/TOR/TUR. The
lower limit of 8 INR tests sets a minimum requirement of at least 3
INR results outside of the INR range for classiﬁcation as TTR b70%, rather
than 1 result (for patients with only 2 INR tests) if the full patient sets
had been used.
3. Results
There were in total 140,078 AF patients and 70,371 VTE patients
with CPRD records within the speciﬁed time-window. Figs. 1 and 2
describe how patients were subsequently excluded. The study pop-
ulation comprised 29,717 incident AF patients and 19,113 incident
VTE patients, who initiated treatment with warfarin. Baseline char-
acteristics of the study population are described in Table 1. At base-
line the mean age (SD) was 73.5 (10.1) years for AF patients and
65.4 (15.9) years for VTE patients, 55.92% of AF patients and
48.24% of VTE patients were male. With respect to CHA2DS2-VASc
score at baseline, 81.34% of AF patients were at high risk of stroke
(CHA2DS2-VASc ≥2).
Due tomore than 75%missing values and fewer than 10 patients re-
spectively, the variables “main spoken language” and “bipolar disease”
were excluded from further analyses.
During the 12 months of follow-up, 87.03% of AF patients were pre-
scribedwarfarin formore than 6months. In the course ofwarfarin treat-
ment, AF patients had on average 15.72 INR tests (SD 8.7) and 68.25%
had intervals between INR tests of less than 56 days [43], 57.41% of
VTE patients were prescribed warfarin for more than 6 months; and
had on average 11.95 INR tests (SD 7.8) and 79.76% had intervals be-
tween INR tests of less than 56 days. Fig. 3 presents the overall percent-
age time spent in the therapeutic range over the studyperiod, for AF and
VTE patients. During warfarin therapy, 43.83% of AF and 36.00% of VTEpatients spent 70% or more time in therapeutic range (TTR ≥ 70%);
and 14.03% of AF patients and 21.62% of VTE patients spent 40% or less
time in therapeutic range (TTR ≤ 40%).
Table 2 presents the patient baseline characteristics with signiﬁcant
effect on TTR (Table S3 in the online supplement provides the results for
all the other predictors). The effect of each variable was fully adjusted
for all other variables. In themultivariate regressionmodel, 14 variables
signiﬁcantly predicted worse anticoagulation control (lower TTR):
being female, younger age (b45 years), underweight/normal BMI
(b25 Kg/m2), smoking, substance abuse (in VTE patients); having
acute respiratory infections, incident cancer (in VTE patients), COPD/
asthma, dementia, diabetes, epilepsy; the chronic use of pain medica-
tion or lipid lowering drugs (in AF patients) and the repeated number
of hospitalisations. No signiﬁcant interactions with age, gender or
Townsend deprivation score were observed at a family-wise adjusted
error rate of 0.05. Overall, the patient baseline characteristics and the
practice random effect together only explained approximately 7% of
the variation in TTR (0.070 in AF patients and 0.068 in VTE patients);
and the explanatory ability of the model decreased further in the sensi-
tivity analysis excluding practice as a random effect (0.021 in AF pa-
tients and 0.044 in VTE patients).The sensitivity analyses of the group
of patients with N 6 months of warfarin treatment or with ≥8 INR tests
showed few differences in the estimates (Table S4 and Tables S5a-b in
appendix).
We used logistic regression to further explore the ability of patient
characteristics to predict poor anticoagulation control (TTR b 70%);
and the patterns of poor anticoagulation control as time spent under
range (TUR) and/or time spent over range (TOR) (Tables 3 and 4). The
variables identiﬁed as signiﬁcant predictors of lower TTR in the original
models also emerged as signiﬁcant predictors of anticoagulation con-
trol. Age was an extremely signiﬁcant predictor of anticoagulation con-
trol (AF: p = 1.8*10−20; VTE: p = 9.4*10−17). Younger patients
(b45 years) were more likely to have poor anticoagulation control
(TTR b 70%), and this was driven by time spent under the INR range
(TUR N 30%). This effect was observed for both AF and VTE patients
(see Tables 3 & 4 respectively for odds ratios). In VTE patients we ob-
served a slightly increased risk of TOR as age increases, with those
older than 80 years having a signiﬁcant increased risk of going over
the INR range. While gender was not signiﬁcantly associated with
poor anticoagulation control overall (TTR b 70%), women with VTE
showed a tendency for TUR (OR 1.19; [CI 1.04-1.37]) and conversely
men did so for TOR (OR 0.83; [CI 0.69-1.00]).
BMI was strongly associated with anticoagulation control (AF: p =
7.7*10−6; VTE: p = 1.4*10−7). A uniform trend in anticoagulation con-
trol with BMI was observed for both AF and VTE patients. As BMI in-
creased, so overall anticoagulation control improved. This effect was
most pronounced in VTE patients, where, compared to normal BMI
(18.5-24.9 kg/m2), odds ratios of 1.56; [CI 0.87-2.79] for underweight
patients (b18.5 kg/m2) dropping to 0.79; [CI 0.66-0.95] for BMI
(25–39.9 kg/m2) and to 0.70; [CI 0.50-0.97] for morbidly obese patients
(≥40 kg/m2) were observed. This effect appears to be driven by TUR,
with a similar trend observed for AF and VTE (see Tables 3 and 4 respec-
tively), again with VTE displaying a more pronounced effect (under-
weight: OR 1.48, [CI 0.93-2.36]; morbidly obese: OR 0.64, [CI 0.46-
0.90]).
Smoking was also a highly signiﬁcant predictor of TTR (AF: p =
2.2*10−5; VTE: p = 4.1*10−8). Compared to non-smokers, both AF
and VTE patients who were current smokers had a signiﬁcantly in-
creased risk of poor anticoagulation control (AF: OR 1.21; [CI 1.06-
1.39] and VTE: OR 1.36; [CI 1.15-1.62]), with a pattern of individual pa-
tients having under-coagulation (AF: OR 1.18; [CI 1.02-1.37] and VTE:
OR 1.23; [CI 1.04-1.45]), over-coagulation (AF: OR 1.24; [CI 1.01-1.52]
and VTE: OR 1.28; [CI 1.02-1.59), and extended periods of both TUR
and TOR (AF: OR 2.00; [CI 1.06-3.77] and VTE: OR 1.95; [CI 1.06-3.60]).
Former smokers did not have a signiﬁcantly increased risk of poor
anticoagulation control.
Fig. 1. Flowchart of study sample selection – AF patients.
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anticoagulation control, with different effects observed in AF and
VTE patients. In AF patients, having a chronic respiratory disease
(COPD or asthma) or heart failure increased the risk of poor
anticoagulation control, but this was not particularly driven by time
spent under or over INR range. In contrast,while AFpatientswith diabe-
tes did not have an increased risk of poor anticoagulation control over-
all, these patients did seem to show a tendency for TUR (OR 1.22; [CI
1.02-1.47]). In VTE patients, having active cancer was strongly associat-
ed with poor anticoagulation control (OR 1.59; [CI 1.22-2.08]), TOR (OR
1.90; [95% FWA CI 1.41-2.57]) and a combination of both TUR and TOR
(OR 3.37; [CI 1.51-7.53]). VTE patients with epilepsy or acute respirato-
ry infections did not have an increased risk of poor anticoagulationcontrol overall, but seem to show a tendency for TUR (OR 1.72; [CI
1.07-2.75] and OR 1.78; [CI 1.02-3.10]; respectively). In contrast, while
VTE patients with chronic liver disease or rheumatoid arthritis also
didn’t have an increased risk of poor anticoagulation control overall,
they did seem to show a tendency for TOR (OR 2.24; [CI 1.06-4.74]
and OR 1.76; [CI 1.05-2.96] respectively).
In both AF and VTE patients, chronic use of pain medications (para-
cetamol, NSAIDs or opioids) increased the risk of poor anticoagulation
control (AF: OR 1.22; [CI 1.07-1.39] and VTE: OR 1.33; [CI 1.09-1.62]).
In VTE, patterns of TOR and both TOR and TUR (but not TUR alone)
were also observed (OR 1.33; [CI 1.09-1.62] and OR 2.35; [CI 1.18-4.70],
respectively). In AF patients, an increasing number of hospitalisations
was signiﬁcantly associated with an increased risk of time spent under
Fig. 2. Flowchart of study sample selection – VTE patients.
254 A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260INR range (TUR N 30%). All other patient baseline characteristics had no
signiﬁcant effect on anticoagulation control.
Themodel revealed reasonable discriminative ability to predict poor
anticoagulation control, as shown by the concordance indexes (C-index
of 0.578 in AF patients and C-index of 0.609 in VTE patients). Table 5
summarises the effects of each predictor on anticoagulation control,
for AF and VTE patients.4. Discussion
In this study we examined patient-level characteristics associated
with anticoagulation control with warfarin (measured as TTR) in a
large representative primary care population from the UK.We observed that in real world clinical practice a minority of pa-
tients achieve good anticoagulation with warfarin (44% AF patients
and 36% VTE patients had TTR ≥ 70%). Applying the results of a previous
study [19], we found that 14.03% of AF patients in our study are likely to
be receiving no beneﬁt at all from warfarin therapy (TTR ≤ 40%). These
rates conﬁrm that poorer anticoagulation control with warfarin is ob-
served in real world clinical practice than in clinical trials [20–22].
We estimated the effects of multiple patient-level characteristics on
TTR and demonstrated that in the ﬁrst twelve months of warfarin use
there is a very high degree of unpredictable variability in TTR. In both
AF and VTE patients, the included patient-level variables and the prac-
tice itself together only explained approximately 7% of the variation in
TTR. This suggests that, even if clinicians are aware of all the variables
shown to correlate with TTR, it is still not possible to accurately predict
Table 1
Baseline characteristics of the study population included in the TTR analysis.
AF patients VTE patients
Baseline Characteristics N = 29,717
(%)
N = 19,113
(%)
Gender
Male 16,617 (55.92) 9,221 (48.24)
Female 13,100 (44.08) 9,892 (51.76)
Age mean (SD)/median, years 73.51 (10.15) 65.41 (15.98)
18-44 327 (1.1) 2,313 (12.10)
45-54 1,046 (3.52) 2,207 (11.55)
55-64 3,862 (13.0) 3,614 (18.91)
65-74 9,113 (30.67) 4,657 (24.37)
75-79 6,359 (21.40) 2,444 (12.79)
≥80 9,010 (30.32) 3,878 (20.29)
Ethnicity
White 17,756 (59.75) 11,338 (59.32)
Black 42 (0.14) 85 (0.44)
Asian 87 (0.29) 72 (0.38)
Other (incl. mixed) 154 (0.52) 89 (0.47)
Unknown 11,678 (39.30) 7,529 (39.39)
Townsend Deprivation Score
Q1 (least deprived) 4,192 (14.11) 2,742 (14.35)
Q2 4,671 (15.72) 2,824 (14.78)
Q3 3,690 (12.42) 2,347 (12.28)
Q4 2,821 (9.49) 2,043 (10.69)
Q5 (most deprived) 1500 (5.05) 1,039 (5.44)
unknown 12,843 (43.22) 8,118 (42.27)
Main spoken language
English 6,500 (21.87) 3,903 (20.42)
Other 77 (0.26) 47 (0.25)
Unknown 23,140 (77.87) 15,163 (79.33)
BMI, kg/m2
b18.5 637 (2.14) 367 (1.92)
18.5-24.9 8,467 (28.49) 4,619 (24.17)
25-29.9 10,336 (34.78) 6,272 (32.82)
30-39.9 7,737 (26.04) 5,333 (27.9)
≥40 1,042 (3.51) 854 (4.47)
Unknown 1,498 (5.04) 1,668 (8.73)
Smoking history
Current smokers 4,641 (15.62) 4,209 (22.02)
Former smoker 9,066 (30.51) 4,450 (23.28)
Non-smoker/never 15,938 (53.63) 10,331 (54.05)
Unknown status 72 (0.24) 123 (0.64)
Alcohol consumption
Non-drinker 2,597 (8.74) 1,839 (9.62)
Ex-drinker 829 (2.79) 454 (2.38)
Current-drinker (unspeciﬁed or rare drinker) 4,171 (7.78) 2,737 (14.32)
Heavy-drinker (≥3u/d) 15,651 (52.67) 8,342 (43.65)
Unknown drinker status 6,469 (21.77) 5,741 (30.04)
Substance Abuse (non-alcohol/tobacco)
Yes 160 (0.54) 278 (1.45)
No 29,557 (99.46) 18,835 (98.55)
Comorbidities:
Acute respiratory infection (within 30 days) 281 (0.95) 223 (1.17)
Bipolar disorder (within 3 months) 2 (0.01) 3 (0.02)
Incident cancer (within 24 months) 1,189 (4.00) 1,966 (10.29)
Chronic kidney disease 5,148 (17.32) 2,303 (12.05)
Chronic liver disease 201 (0.68) 175 (0.92)
Chronic lung disease (COPD, Asthma) 4,628 (15.57) 3,092 (16.18)
Chronic use of pain medication (within
12 months)
7,737 (26.04) 5,698 (29.81)
Dementia 179 (0.60) 322 (1.68)
Depression (within 3 months) 294 (0.99) 273 (1.43)
Diabetes 3,671 (12.35) 1,605 (8.40)
Epilepsy 326 (1.10) 356 (1.86)
Heart failure 3,672 (12.36) 857 (4.48)
Hyperlipidaemia (within 12 months) 600 (2.02) 237 (1.24)
Use of lipid lowering drugs (within 3 months) 13,044 (43.89) 4,293 (22.46)
Hypertension 15,854 (53.35) 6,378 (33.37)
History of bleeding 3,934 (13.24) 2,207 (11.55)
History of Stroke 3,207 (10.79) 855 (4.47)
Table 1 (continued)
AF patients VTE patients
Baseline Characteristics N = 29,717
(%)
N = 19,113
(%)
Comorbidities:
Osteoarthritis 7,572 (25.48) 4,268 (22.33)
Rheumatoid Arthritis 404 (1.36) 416 (2.18)
Thyroid disease 2,428 (8.17) 1,316 (6.89)
Vascular disease 3,252 (10.94) 1,144 (5.99)
Number of pre-speciﬁed conditions
Mean (SD) 2.61 (1.76) 1.99 (1.74)
0 3,238 (10.9) 4,436 (23.21)
1-2 12,066 (40.60) 8,233 (43.08)
3-4 10,109 (34.02) 4,604 (24.09)
≥5 4,304 (14.48) 1,840 (9.63)
CHA2DS2-VASc risk score
Mean (SD) 2.9 (1.5) NA
0 1,761 (5.93) NA
1 3,784 (12.73) NA
≥2 24,172 (81.34) NA
HAS-BLED risk score
Mean (SD)/Median 2.8 (1.3) NA
0 837 (2.82) NA
1 4,090 (13.76) NA
2 7,651 (25.75) NA
≥3 17,139 (57.67) NA
Annual consultation rate, mean (SD) 13.86 (9.69) 14.10 (10.82)
0 240 (0.81) 196 (1.03)
1-4 2,708 (9.11) 2,201 (11.52)
5-10 9,722 (32.72) 6,107 (31.95)
11-20 11,746 (39.53) 6,815 (35.66)
21-50 5,054 (17.01) 3,579 (18.73)
N50 247 (0.83) 215 (1.12)
Annual hospitalisation rate, mean (SD) 1.14 (2.95) 2.05 (3.93)
0 6,136 (20.65) 1,728 (9.04)
1-4 8,731 (29.38) 7,639 (39.97)
5-10 337 (1.13) 644 (3.37)
11-20 36 (0.12) 158 (0.83)
N20 15 (0.05) 26 (0.14)
Unknown 14,462 (48.67) 8,918 (46.66)
⁎vascular disease (includes prior myocardial infarction, peripheral artery disease or aortic
plaque).
NA – Not applicable.
255A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260an individual’s TTR on warfarin therapy. Other patient-related unmea-
sured factors (e.g. poor compliance [40,44–46] and polymorphisms in
the genes involved in the metabolism of warfarin [47,48]) may be
responsible for some of the remaining variability in TTR. Removal of
practice from themodels greatly reduced their explanatory ability, indi-
cating that quality of caremight also be responsible for a substantial var-
iability in TTR [49,50] Theseﬁndings highlight thedifﬁculty ofmanagingFig. 3. Time spent in the Therapeutic Range (TTR) over the study period, for AF and VTE
patients.
Table 2
Patient baseline characteristics with signiﬁcant effect on TTR - multivariable mixed regression model.
AF patients VTE patients
Baseline Characteristics Adjusted effect 95 % FWA CI† p‡ Adjusted effect 95% FWA CI† p‡
Gender
Female −0.0046 −0.0143 0.0051 −0.0169 −0.0297 −0.0042 ***
Age, years
18-44 - - - - - -
45-54 0.0485 0.0012 0.0958 * 0.0610 0.0364 0.0856 ***
55-64 0.0756 0.0323 0.1189 *** 0.0792 0.0564 0.1020 ***
65-74 0.0981 0.0554 0.1407 *** 0.0890 0.0662 0.1118 ***
75-79 0.0996 0.0564 0.1428 *** 0.0814 0.0552 0.1075 ***
≥80 0.0806 0.0374 0.1237 *** 0.0579 0.0330 0.0827 ***
BMI, kg/m2
b18.5 −0.0179 −0.0486 0.0129 −0.0540 −0.0984 −0.0097 **
18.5-24.9 - - - - - -
25-29.9 0.0111 0.0000 0.0222 * 0.0201 0.0041 0.0360 **
30-39.9 0.0208 0.0084 0.0332 *** 0.0298 0.0128 0.0467 ***
≥40 0.0144 −0.0111 0.0398 0.0534 0.0221 0.0847 ***
Unknown −0.0094 −0.0313 0.0125 −0.0022 −0.0266 0.0223
Smoking history
Non-smoker/never - - - - - -
Current smokers −0.0244 −0.0375 −0.0114 *** −0.0364 −0.0522 −0.0207 ***
Former smoker −0.0100 −0.0203 0.0002 −0.0109 −0.0260 0.0042
Unknown status −0.0420 −0.1318 0.0478 −0.0497 −0.1261 0.0267
Substance Abuse (non-alcohol/tobacco)
Yes −0.0362 −0.0958 0.0235 −0.1081 −0.1589 −0.0574 ***
Comorbidities:
Acute respiratory infection (within 30 days) −0.0188 −0.0642 0.0265 *** −0.0261 −0.0823 0.0302
Incident cancer (within 24 months) −0.0103 −0.0337 0.0131 −0.0636 −0.0871 −0.0401 ***
Chronic lung disease (COPD, Asthma) −0.0189 −0.0333 −0.0046 *** −0.0218 −0.0421 −0.0015 *
Chronic use of pain medication (within 12 months) −0.0137 −0.0266 −0.0009 * −0.0289 −0.0471 −0.0107 ***
Dementia −0.0435 −0.0999 0.0129 −0.0561 −0.1041 −0.0082 **
Diabetes −0.0201 −0.0358 −0.0044 ** −0.0283 −0.0535 −0.0031 *
Epilepsy −0.0528 −0.0950 −0.0105 ** −0.0561 −0.1013 −0.0108 **
Use of lipid lowering drugs (within 3 months) 0.0150 0.0026 0.0275 ** −0.0043 −0.0245 0.0159
Annual hospitalisation rate
0 - - - - - -
1-4 −0.0095 −0.0222 0.0033 0.0121 −0.0101 0.0343
5-10 −0.0735 −0.1157 −0.0314 *** −0.0122 −0.0510 0.0266
11-20 −0.0985 −0.2233 0.0264 −0.0424 −0.1112 0.0265
N20 −0.0947 −0.2884 0.0989 0.0109 −0.1507 0.1725
Unknown −0.0094 −0.0298 0.0109 0.0337 0.0005 0.0669 *
All coefﬁcients are in units of TTR. ‡Signiﬁcance at three thresholds is reported, all thresholds have been adjusted for family-wise error rate: *p b 0.05 (0.00082) **p b 0.001 (0.00016) ***p b
0.0001 (0.000016 )† 95 %FWA CI:−Family-Wise-Adjusted Conﬁdence Interval. Corresponds to 99.918% CI.
256 A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260warfarin patients in real world clinical practice. In a study by Nieuwlaat
et al. showed that the introduction of a computer based warfarin dosing
systemdid not improve TTR compared to usual care [51], although there
are recognised other beneﬁts to computer dosing [52]. More studies are
therefore needed to understand patient behaviour and practice perfor-
mance factors that might affect warfarin anticoagulation control.
Although the patient characteristics included in our model had a
poor ability to predict an individual’s TTR on warfarin therapy, the abil-
ity to predict poor anticoagulation control (deﬁned as TTR b 70%) was
somewhat better (C-index of 0.578 in the group of AF patients and C-
index of 0.609 in the group of VTE patients). Additionally, a number of
patient characteristics were associated with a signiﬁcantly increased
risk of patients spending N 30%of time either above or below the recom-
mended INR range of 2.0 – 3.0. Poor anticoagulation control driven by
time spent under INR range was observed in younger patients, under-
weight patients, and in AF patients with increased number of
hospitalisations. In VTE patients we observed a slightly increased risk
of poor anticoagulation control driven by time spent over INR range
with increasing age, which was signiﬁcant in those older than
80 years. Poor anticoagulation control with ﬂuctuation between time
spent under and over INR range was seen in both AF and VTE patients
whowere current smokers (but not in former smokers), in those chron-
ically using pain medications and in VTE patients with active cancer.That younger AF patients (b45 years) are signiﬁcantly more likely to
spend time under INR range is perhaps due to their lower compliance
withwarfarin therapy. An increased number of repeated hospitalisations
has been shown to increase the likelihood of having sub-therapeutic INR.
This is in line with a previous study, in which repeated hospitalisations
was as a strong predictor of lower TTR [17] due to changes in diet, health
status and therapy during and after a patient’s hospitalisation. It is there-
fore clear that performing an accurate medication reconciliation is criti-
cal for a successful transition of warfarin patients from secondary to
primary care.
Smoking status was identiﬁed as a strong predictor of poor
anticoagulation control in both AF and VTE patients. Our study shows
that current smokers aremore likely to experience poor TTR (b70%), driv-
en by both sub and supra-therapeutic INR. Interestingly, the effect of
smoking appears to diminish after patients give up smoking. Studies sug-
gest that smokingmay interact with warfarin, but the clinical evidence of
this interaction remains inconclusive [33,53]. Based on this ﬁnding,
smoking cessation counselling should be instituted prior to initiation of
warfarin therapy. The chronic use of painmedications was also identiﬁed
as a predictor of poor anticoagulation control in both AF and VTE patients,
again driven by an increased likelihood of ﬂuctuating between sub and
supra-therapeutic INR. The interaction between warfarin and analgesics
has been extensively documented [35,37,54]. Some of these drugs are
Table 3
Logistic regression analysis in AF group: predictors of poor anticoagulation control (TTR b 70%) and patterns of time spent under (TUR) and/or over range (TOR).
TTR b 70% TUR N30% TOR N30% TUR & TOR N30%
AF patients baseline characteristics OR 95% FWA CI OR 95% FWA CI OR 95% FWA CI OR 95% FWA CI
Age, years
18-44 1 1 1 1
45-54 0.69 0.40 1.19 0.81 0.48 1.35 1.21 0.54 2.73 3.38 0.10 115.35
55-64 0.55 0.33 0.92 0.53 0.33 0.86 1.26 0.59 2.66 2.41 0.08 74.38
65-74 0.42 0.26 0.69 0.44 0.28 0.70 0.98 0.46 2.06 1.44 0.05 44.05
75-79 0.42 0.26 0.70 0.43 0.27 0.70 0.96 0.45 2.04 2.14 0.07 65.98
≥80 0.49 0.29 0.80 0.50 0.31 0.80 1.04 0.49 2.20 2.57 0.08 78.72
BMI, kg/m2
b18.5 1.28 0.91 1.78 1.08 0.75 1.54 1.01 0.61 1.66 1.32 0.34 5.15
18.5-24.9 1 1 1 1
25-29.9 0.91 0.82 1.02 0.89 0.78 1.02 0.94 0.78 1.13 0.92 0.50 1.69
30-39.9 0.86 0.75 0.97 0.80 0.69 0.93 0.95 0.78 1.17 0.84 0.43 1.67
≥40 0.81 0.62 1.05 0.85 0.63 1.15 0.94 0.62 1.42 0.70 0.16 3.10
Unknown 1.01 0.81 1.27 0.98 0.76 1.26 1.04 0.74 1.48 1.15 0.37 3.52
Smoking history
Non-smoker/never 1 1 1 1
Current smokers 1.21 1.06 1.39 1.18 1.02 1.37 1.24 1.01 1.52 2.00 1.06 3.77
Former smoker 1.06 0.95 1.17 1.00 0.88 1.12 1.08 0.91 1.28 1.34 0.76 2.37
Unknown status 1.52 0.50 4.61 1.00 0.30 3.31 2.20 0.63 7.63 2.67 0.08 92.00
Comorbidities:
Chronic lung disease (COPD, Asthma) 1.23 1.06 1.42 1.14 0.97 1.35 1.02 0.81 1.29 1.29 0.64 2.59
Chronic use pain medication (within 12 months) 1.22 1.07 1.39 1.08 0.93 1.26 1.21 0.99 1.49 1.32 0.68 2.53
Diabetes 1.10 0.94 1.29 1.22 1.02 1.47 0.93 0.72 1.21 1.34 0.61 2.92
Heart failure 1.19 1.01 1.39 0.96 0.80 1.16 1.25 0.98 1.58 1.33 0.64 2.78
Annual hospitalisation rate
0 1 1 1 1
1-4 1.10 0.97 1.26 1.17 1.01 1.37 1.02 0.82 1.27 1.20 0.55 2.60
5-10 1.50 0.91 2.45 1.95 1.20 3.17 0.88 0.41 1.90 2.13 0.34 13.41
11-20 2.30 0.47 11.30 2.41 0.61 9.62 1.48 0.23 9.39 3.75 0.10 140.15
N20 1.79 0.11 30.26 0.49 0.01 18.69 1.23 0.03 47.41 N/A
Unknown 1.06 0.86 1.30 0.97 0.76 1.25 1.05 0.75 1.48 0.91 0.25 3.29
TUR – Time Under Therapeutic Range (INR b 2); TOR – Time Over Therapeutic Range (INR N 3).
95 % FWA CI: - Family-Wise-Adjusted Conﬁdence Interval. Corresponds to 99.918% CI.
257A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260available over the counter,withparacetamol being a very commonly used
analgesic in patients receiving anticoagulant therapy. This ﬁnding should
enhance clinicians’ awareness of this common drug-drug interaction
when counselling patients prior to initiation of warfarin.
In VTE patients, incident cancer was a strong predictor of poor
anticoagulation control, driven by supra-therapeutic INR, and a combi-
nation of sub and supra-therapeutic INR. Drug-drug interactions and cy-
clical therapy courses may be the cause of this observation. This ﬁnding
underscores NICE guidance that LMWHmonotherapy is more clinically
effective than dose-adjustedwarfarin for treatment of VTE in cancer pa-
tients [55].
Previous studies have explored the effect of multiple patient-level
predictors of anticoagulation control with warfarin [17,18]. Similar to
our study, the VARIA investigators concluded that age less than
55 years, repeat hospitalisations, cancer and chronic liver disease nega-
tively affected TTR [17]. Apostolakis et al. [18,56] proposed the use of
SAMe-TT2R2 score (Sex female, Age less than 60, Medical history
[more than two comorbidities], Treatment strategy [rhythm control],
Tobacco use [doubled], Race [doubled]) to discriminate patients with
AF who are likely to have labile INR values during warfarin treatment.
In the VARIA study the majority of the population (N90%) was male
and included AF and VTE patients in the same model. The SAMe-
TT2R2 scorewas derived from data from a clinical trial (AFFIRM). There-
fore, to our knowledge this is the ﬁrst study including a representative
sample of both AF and VTE patients in UK population, using real world
data from primary care practice.
A major strength of this study was the large cohort size and the use
of routine clinical data representative of the general UK population
[25–29], that better reﬂects the management of warfarin patients’ in
general clinical practice than clinical trials.Our data demonstrated good quality for assessing warfarin use and
anticoagulation control (measured as TTR) in clinical practice. A pre-
scription doesn’t necessarilymean that a patient has taken a drug. How-
ever, our estimates were based on continuous prescriptions and INR
tests over 12 months (patients with only one warfarin prescription
and/or less than two INR tests were excluded from the analysis) and
this is likely to be indicative of at least some regular use ofwarfarin. Dur-
ing the 12 months of observation, 68.25% of AF patients and 79.76% of
VTE patients had intervals between INR tests of less than 56 days, and
had on average 15 and 10 INR tests, respectively. Moreover, this study
was performed using the principle of effectiveness, whereby it is the
percentage of time spent within the recommended INR range that is
being assessed, rather than the taking of warfarin. A comparison of
baseline characteristics between patients excluded for having only one
warfarin prescription or fewer than 2 INR tests and those included in
the TTR analyses showed little difference (Supplementary Information
Table S1). However, it cannot be ruled out that the exclusion of these
patients may have led to bias due to imbalances in unmeasured
characteristics.
The use of statistical adjustment for multiple testing (FWA) reduces
the number of false positive results and consequently there is strong
evidence supporting each individual ﬁnding of signiﬁcance. The draw-
backs arewider conﬁdence intervals and the potential failure to identify
some factors that have small but real associations with anticoagulation
control.
Misclassiﬁcation of diagnosis is possible, since we didn’t have infor-
mation on the diagnostic criteria. However, several studies have con-
ﬁrmed the validity of the diagnostic and prescription data in the CPRD
for research [25–30]. Misclassiﬁcation due to missing data on ethnicity
is possible, since this is not routinely recorded by general practitioners.
Table 4
Logistic regression analysis in VTE group: predictors of poor anticoagulation control (TTR b 70%) and patterns of TUR and/or TOR.
TTR b 70% TUR N30% TOR N30% TUR & TOR N30%
VTE patients baseline Characteristics OR 95% FWA CI OR 95% FWA CI OR 95% FWA CI OR 95% FWA CI
Gender
Female 1.07 0.94 1.23 1.19 1.04 1.37 0.83 0.69 1.00 1.16 0.68 1.97
Age, years
18-44 1 1 1 1
45-54 0.64 0.49 0.85 0.61 0.48 0.79 1.03 0.70 1.53 1.18 0.40 3.45
55-64 0.57 0.44 0.73 0.47 0.37 0.60 1.12 0.79 1.60 1.08 0.39 3.01
65-74 0.51 0.39 0.66 0.42 0.33 0.53 1.25 0.88 1.78 1.04 0.37 2.88
75-79 0.54 0.40 0.73 0.40 0.30 0.52 1.31 0.89 1.94 0.91 0.28 2.97
≥80 0.64 0.48 0.85 0.45 0.35 0.59 1.46 1.01 2.13 1.38 0.47 4.03
Townsend Deprivation Score
Q1 (least deprived) 1 1 1 1
Q2 1.15 0.91 1.46 1.14 0.90 1.44 1.01 0.73 1.40 1.22 0.45 3.32
Q3 1.29 1.00 1.66 1.15 0.89 1.47 1.13 0.81 1.58 1.28 0.46 3.52
Q4 1.15 0.89 1.50 1.14 0.87 1.47 0.92 0.64 1.32 1.27 0.44 3.63
Q5 (most deprived) 1.28 0.90 1.83 1.10 0.78 1.55 1.15 0.73 1.80 1.24 0.33 4.59
unknown 1.27 0.91 1.79 1.19 0.84 1.68 1.16 0.71 1.88 1.46 0.35 6.12
BMI, kg/m2
b18.5 1.56 0.87 2.79 1.48 0.93 2.36 0.95 0.50 1.79 1.50 0.37 6.09
18.5-24.9 1 1 1 1
25-29.9 0.80 0.67 0.95 0.88 0.74 1.04 0.82 0.65 1.03 0.87 0.45 1.69
30-39.9 0.79 0.66 0.95 0.76 0.63 0.91 1.01 0.79 1.28 0.82 0.40 1.66
≥40 0.70 0.50 0.97 0.64 0.46 0.90 1.06 0.68 1.65 0.50 0.10 2.53
Unknown 0.87 0.66 1.13 0.90 0.70 1.16 1.06 0.76 1.49 1.19 0.49 2.93
Smoking history
Non-smoker/never 1 1 1 1
Current smokers 1.36 1.15 1.62 1.23 1.04 1.45 1.28 1.02 1.59 1.95 1.06 3.60
Former smoker 1.06 0.91 1.24 1.03 0.88 1.21 1.07 0.87 1.33 1.14 0.59 2.19
Unknown status 1.53 0.56 4.15 0.71 0.26 1.88 2.26 0.87 5.90 1.72 0.14 21.97
Comorbidities:
Acute respiratory infection (within 30 days) 1.11 0.62 1.99 1.78 1.02 3.10 0.74 0.31 1.79 3.31 0.64 17.00
Incident cancer (within 24 months) 1.59 1.22 2.08 1.05 0.81 1.36 1.90 1.41 2.57 3.37 1.51 7.53
Chronic liver disease 1.25 0.60 2.63 0.74 0.37 1.51 2.24 1.06 4.74 3.53 0.66 19.00
Epilepsy 1.51 0.89 2.58 1.72 1.07 2.75 0.94 0.48 1.86 1.17 0.15 8.92
Chronic use of pain medication (within 12 months) 1.33 1.09 1.62 1.16 0.96 1.41 1.33 1.03 1.70 2.35 1.18 4.70
Rheumatoid Arthritis 1.24 0.77 1.98 0.93 0.59 1.47 1.76 1.05 2.96 1.42 0.28 7.16
TUR – Time Under Therapeutic Range (INR b 2); TOR – Time Over Therapeutic Range (INR N 3).
95 % FWA CI: - Family-Wise-Adjusted Conﬁdence Interval. Corresponds to 99.918% CI.
258 A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260Additionally, for the diagnosis of some conditions that are stigmatised
or difﬁcult to recognise such as alcohol consumption, substance abuse,
dementia or bipolar disorder, our database may lack sensitivity. There-
fore, no deﬁnitive conclusions should be drawn regarding the effect of
these variables on anticoagulation control with warfarin.Table 5
Summary of the effects of each predictor on anticoagulation control, in AF and VTE
patients.
Tendency of TTR failure
Poor TTR Under Over
AF & VTE Age b 45 yr Age b 45 yr Age N 80 yr
BMI b 18.5 kg/m2 BMI b 18.5 kg/m2
Smoking Smoking Smoking
Pain meds Pain meds Pain meds
AF Diabetes
Hospitalisations ≥ 1
COPD or Asthma
Heart Failure
VTE Gender Female Male
Active Cancer Cancer Cancer
Liver disease Liver disease
Rheumatoid Arth. Rheumatoid Arth.
ARI, Epilepsy
Most deprived
ARI - Acute Respiratory Infections.Misclassiﬁcation of prescription data is possible for drugs that may
be purchased over the counter (antiplatelets and analgesics). However,
it is likely that most prescriptions are issued in primary care, especially
among people over 60 years. Misclassiﬁcation of “active cancer” is pos-
sible since the coding of an incident cancer in CPRD might have been
done retrospectively. This is a recognised limitation since in CPRD we
don’t have information on hospital prescriptions.
Confounding was reduced by adjustment for a wide range of poten-
tial confounding/predictor variables, but residual confounding is possi-
ble due to risk factors that have not been considered, or to potential
changes in risk factors during follow up.
This study provides evidence that in the ﬁrst twelve months of war-
farin use there is a high amount of unpredictable variability in an indi-
vidual’s TTR. We identiﬁed multiple patient-level predictors of poor
anticoagulation control (TTR b 70%) in patients who initiated warfarin
treatment. Additionally, a number of patient characteristics were
found to be associated with a signiﬁcantly increased risk of patients
spending time under or over the recommended INR range 2.0 – 3.0.
Our results echo ﬁndings from previous studies and provide a more
comprehensive analysis of the patterns of poor anticoagulation control.
These ﬁndings conﬁrm the difﬁculty of achieving high-quality
anticoagulation control with warfarin in real world clinical practice
and can be used to identify warfarin patients who require closer moni-
toring or innovative management strategies to optimise the outcomes
of oral anticoagulant therapy. Further research in this area should inves-
tigate the ability of the identiﬁed patient-level predictors of poor
259A.F. Macedo et al. / Thrombosis Research 136 (2015) 250–260anticoagulation control (due to high INRs and/or low INRs) to also iden-
tify subsequent unintended outcomes of warfarin treatment (bleeding/
stroke/systemic embolism).
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